Advertisement

Advertisement
Apar Kishor Ganti, MD, on NSCLC: Real-World Adherence and Persistence of ALK Inhibitors

Apar Kishor Ganti, MD, on NSCLC: Real-World Adherence and Persistence of ALK Inhibitors

AACR 2020: Mortality Rate in Patients With Thoracic Cancers Infected With COVID-19

First results from the TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion) registry for thoracic cancers—presented by Marina C. Garassino, MD, at the American Association for Cancer Research (AACR) Virtual Annual Meeting in the COVID-19 and Cancer Session—indicate a high mortality rate from COVID-19 in patients with thoracic malignancies.

AACR 2020: ctDNA May Be a Prognostic Biomarker of Disease Recurrence in Patients With Lung Cancer

The TRACERx study investigated phylogenetic tracking and minimal residual disease detection using circulating tumor DNA (ctDNA) profiling following resection in patients with stage I to III non–small cell lung cancer. The investigators found that ctDNA is an adjuvant biomarker capable of both detecting MRD following surgery and defining the clonality of relapsing disease. Abbosh et al will present the data at the American Association for Cancer Research (AACR) Annual Meeting.

Addition of Pembrolizumab to Docetaxel for Previously Treated Immunotherapy-Naive Patients With Advanced NSCLC

In a single-institution phase II trial reported in JAMA Oncology, Arrieta et al found that the addition of pembrolizumab to docetaxel improved objective response rate and progression-free survival in immunotherapy-naive patients with advanced non–small cell lung cancer (NSCLC) who experienced disease progression after first-line platinum-based chemotherapy.

First-Line Durvalumab With or Without Tremelimumab vs Chemotherapy for Metastatic NSCLC: MYSTIC Study

As reported in JAMA Oncology by Naiyer A. Rizvi, MD, and colleagues, the phase III MYSTIC trial showed no overall survival benefit with durvalumab vs chemotherapy, or overall or progression-free survival benefit with durvalumab/tremelimumab vs chemotherapy, as first-line treatment in patients with non–small cell lung cancer (NSCLC) with PD-L1 tumor expression ≥ 25%.

Activity of Pembrolizumab in Patients With NSCLC Brain Metastases

Activity of Pembrolizumab in Patients With NSCLC Brain Metastases

As reported in The Lancet Oncology by Sarah B. Goldberg, MD, MPH, and colleagues, continued follow-up of the non–small cell lung cancer (NSCLC) cohort of a single-institution phase II trial showed that pembrolizumab produced responses in patients with brain metastases and programmed cell death ligand 1 expression ≥ 1%.

Advertisement


Advertisement